Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT03914612||Recruiting||Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer||
||NIH / Other||
||810||Female||18 Years and older (Adult, Older Adult)||NCT03914612||NCI-2019-02186
|July 16, 2019||June 30, 2023||June 30, 2023||April 15, 2019||September 10, 2019||